It has been proven that administration of Eritoran protects mice from lethal influenza infection by blocking OxPAPC-dependent activation of TLR4 and that the harmful TLR4-mediated signaling can be inhibited also in this case by TLR4 antagonists directly interacting with MD-2 [50]. This evidence concerns the gene TLR4 and influenza.